174 completed, 36 terminated, 27 unknown, 12 withdrawn. 138 Phase 1, 92 Phase 2, 24 Not applicable, 24 Phase 3, 4 Early Phase 1.
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma PET-CTandct- DNAdetection, golidocitinib, Placebo - Maintenance Treatment of Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Fudan University | 136 | 2026-03-27 | 2026-03-31 |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib, Gemcitabine, Bendamustine - Lymphoma | Phase 3 | Recruiting | SecuraBio | 124 | 2025-05-19 | 2026-04-06 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. ARV-393, Glofitamab - Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 1 | Recruiting | Arvinas Inc. | 329 | 2024-09-05 | 2026-09-04 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight CEP + Dasatinib + Azacitidine - Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 4 | Active not recruiting | Zhengzhou University | 34 | 2023-10-21 | 2025-07-01 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types No interventions need to be specified for this study - Lymphoma, Extranodal Lymphoma | Unknown | Ruijin Hospital | 10000 | 2023-07-01 | 2023-06-18 | |
| Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. Rituximab, Gemcitabine, Dexamethasone - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Not applicable | Unknown | Ou Bai, MD/PHD | 34 | 2023-03-23 | 2023-04-20 |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma Anti CD30 CAR-T Cell Injection - Hodgkin Lymphoma, NK/T Cell Lymphoma | Early Phase 1 | Unknown | Zhejiang University | 9 | 2022-02-10 | 2022-01-26 |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Azacitidine, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2022-01-01 | 2022-01-05 |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
Showing 20 of 272. Sign in to see all of them.
Lymphoma, Large-Cell, Anaplastic (239) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (202) · Lymphoma, Large B-Cell, Diffuse (199) · Lymphoma, Follicular (188) · Leukemia, Lymphocytic, Chronic, B-Cell (185) · Lymphoma, Mantle-Cell (185) · Burkitt Lymphoma (182) · Lymphoma, B-Cell, Marginal Zone (182) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (179) · Lymphoma, T-Cell, Cutaneous (177) · Lymphoma, Non-Hodgkin (176) · Mycosis Fungoides (173) · Hodgkin Disease (172) · Lymphoma, Large-Cell, Immunoblastic (167)
Hemic and Lymphatic Diseases (272) · Immune System Diseases (272) · Immunoproliferative Disorders (272) · Lymphadenopathy (272) · Lymphatic Diseases (272) · Neoplasms by Histologic Type (263) · Neoplasms (244) · Lymphoproliferative Disorders (242) · Hematologic Diseases (219) · Leukemia, Lymphoid (215) · Lymphoma, T-Cell (214) · Lymphoma, B-Cell (206) · Disease Attributes (196) · Pathologic Processes (196) · Pathological Conditions, Signs and Symptoms (196)
Cyclophosphamide (38) · fludarabine phosphate (27) · Peripheral Blood Stem Cell Transplantation (25) · Doxorubicin (18) · Etoposide (18) · Whole-Body Irradiation (18) · Vincristine (17) · Cyclosporine (16) · Mycophenolic Acid (16) · Prednisone (16) · Bortezomib (12) · Busulfan (12) · Tacrolimus (12) · Antilymphocyte Serum (11) · Methotrexate (11)
National Cancer Institute (NCI) (43) · Fred Hutchinson Cancer Center (15) · Mayo Clinic (12) · City of Hope Medical Center (10) · Memorial Sloan Kettering Cancer Center (10) · M.D. Anderson Cancer Center (8) · Case Comprehensive Cancer Center (7) · Northwestern University (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Jonsson Comprehensive Cancer Center (6) · National Institutes of Health Clinical Center (CC) (6) · Roswell Park Cancer Institute (5) · University of Medicine and Dentistry of New Jersey (5) · Wake Forest University Health Sciences (5) · Barbara Ann Karmanos Cancer Institute (4)
United States (212) · China (20) · Italy (16) · Canada (12) · France (12) · Germany (11) · United Kingdom (11) · Belgium (8) · Switzerland (6) · South Korea (5) · Spain (5) · Netherlands (4) · Australia (3) · Denmark (3) · Slovakia (3)
David Maloney (4) · Shivaani Kummar, MD (4) · Ajay Gopal (3) · Brenda Sandmaier (3) · John A. Glaspy, MD, MPH (3) · Roger Strair, MD, PhD (3) · Thomas E. Witzig, MD (3) · Abhinav Deol, M.D. (2) · Alex F Herrera (2) · Ann Woolfrey (2) · Barbara Pro, MD (2) · Craig C. Hofmeister, MD (2) · David G. Savage, MD (2) · David J. Straus, MD (2) · David R. Spriggs, MD (2)
PMID 32499241, PMID 11410496, PMID 12525530, PMID 14630685, PMID 15459300, PMID 16135477, PMID 16148284, PMID 16710026, PMID 17119113, PMID 17397698, PMID 18226581, PMID 18327587, PMID 18463792, PMID 18698002, PMID 19170225, PMID 19451403, PMID 19789320, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 20942843, PMID 21135857, PMID 21247755, PMID 21498721, PMID 21715313, PMID 22259028, PMID 22337718, PMID 22480131, PMID 23256542, PMID 23335369, PMID 23358983, PMID 23393050, PMID 24057042, PMID 24241210, PMID 24352795, PMID 24474568, PMID 24493716, PMID 24530972, PMID 25113753, PMID 25135997, PMID 25213183, PMID 25267740, PMID 25403207, PMID 25482745, PMID 25921059, PMID 26077240, PMID 26109202, PMID 26175532
P30CA015704 (12), P30CA015083 (8), P30CA033572 (8), P30CA072720 (6), P30CA016672 (5), P30CA043703 (5), P01CA018029 (4), P30CA036727 (4), U01CA062491 (4), U01CA076576 (4), U01CA099168 (4), U10CA032102 (4), P30CA006973 (3), P30CA014520 (3), P30CA016058 (3)